These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 1524908)

  • 1. Phase II study of cytarabine in Hodgkin's disease. The EORTC Lymphoma Cooperative Group.
    Thomas J; de Pauw B; Hagenbeek A; Somers R; Carde P; Tirelli U; Duez N
    Eur J Cancer; 1992; 28A(4-5):857-9. PubMed ID: 1524908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modified outpatient dexamethazone, cytarabine and cisplatin regimen may lead to high response rates and low toxicity in lymphoma.
    Kanat O; Ozet A; Ataergin S; Arpaci F; Kuzhan O; Komurcu S; Ozturk B; Ozturk M
    Med Princ Pract; 2010; 19(5):344-7. PubMed ID: 20639655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose cytarabine and mitoxantrone as salvage therapy for refractory non-Hodgkin's lymphoma.
    Wang WS; Tzeng CH; Chiou TJ; Liu JH; Hsieh RK; Yen CC; Chen PM
    Jpn J Clin Oncol; 1997 Jun; 27(3):154-7. PubMed ID: 9255269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
    Haq R; Sawka CA; Franssen E; Berinstein NL
    Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie.
    Raemaekers J; Burgers M; Henry-Amar M; Pinna A; Mandard A; Monfardini S; Hagenbeek A; Breed W; Carde P; Vovk M; van Hoof A; Thomas J; Noordijk E
    Ann Oncol; 1997; 8 Suppl 1():111-4. PubMed ID: 9187443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.
    Tessoulin B; Thomare P; Delande E; Moynard J; Gastinne T; Moreau A; Bossard C; Mahé B; Blin N; Dubruille V; Touzeau C; Boudreault JS; Perrin F; Lok A; Guillaume T; Garnier A; Peterlin P; Gallas P; Chevallier P; Moreau P; Le Gouill S
    Ann Hematol; 2017 Jun; 96(6):943-950. PubMed ID: 28374163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Early phase II study of MST-16 (sobuzoxane) on malignant lymphoma].
    Tominaga N; Teshima H; Hiraoka A; Masaoka T; Ariyoshi Y; Suzuki H; Kimura I; Ohnoshi T; Hayashi K; Arima T
    Gan To Kagaku Ryoho; 1991 Nov; 18(14):2441-6. PubMed ID: 1952963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation.
    Colwill R; Crump M; Couture F; Danish R; Stewart AK; Sutton DM; Scott JG; Sutcliffe SB; Brandwein JM; Keating A
    J Clin Oncol; 1995 Feb; 13(2):396-402. PubMed ID: 7844600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma, and multiple myeloma: a Southwest Oncology Group study.
    Jones SE; Tucker WG; Haut A; Tranum BL; Vaughn C; Chase EM; Durie BG
    Cancer Treat Rep; 1977 Dec; 61(9):1617-21. PubMed ID: 340032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of refractory Hodgkin's disease with high-dose cytosine arabinoside and mitoxantrone in combination. Results of a clinical phase II study of the German Hodgkin Study Group.
    Hiddemann W; Schmitz N; Pfreundschuh M; Pflüger KH; Ollech-Chwoyka J; Tirier C; Maschmeyer G; Kirchner H; Wagner T; Koch P
    Cancer; 1990 Sep; 66(5):838-43. PubMed ID: 2386912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial.
    Ferreri AJ; Reni M; Foppoli M; Martelli M; Pangalis GA; Frezzato M; Cabras MG; Fabbri A; Corazzelli G; Ilariucci F; Rossi G; Soffietti R; Stelitano C; Vallisa D; Zaja F; Zoppegno L; Aondio GM; Avvisati G; Balzarotti M; Brandes AA; Fajardo J; Gomez H; Guarini A; Pinotti G; Rigacci L; Uhlmann C; Picozzi P; Vezzulli P; Ponzoni M; Zucca E; Caligaris-Cappio F; Cavalli F;
    Lancet; 2009 Oct; 374(9700):1512-20. PubMed ID: 19767089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of cis-dichlorodiammineplatinum (II) in advanced malignant lymphoma: a study of the cancer and acute leukemia group B.
    Cavalli F; Jungi WF; Nissen NI; Pajak TF; Coleman M; Holland JF
    Cancer; 1981 Nov; 48(9):1927-30. PubMed ID: 7197582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A phase II study of mitoxantrone in refractory and relapsed malignant lymphomas. Cooperative Study Group of Mitoxantrone in Malignant Lymphomas].
    Kimura I; Ohnoshi T; Ogawa M; Sampi K; Masaoka T; Yamada K; Ohta K; Kitani T; Kawagoe H; Shirakawa S
    Gan To Kagaku Ryoho; 1986 Sep; 13(9):2800-6. PubMed ID: 3753026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease.
    Cummings FJ; Kim K; Neiman RS; Comis RL; Oken MM; Weitzman SA; Mann RB; O'Connell MJ
    J Clin Oncol; 1991 Apr; 9(4):565-71. PubMed ID: 2066753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
    Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
    Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methyl-glyoxal bis guanyl hydrazone (methyl-GAG, MGBG) in lymphoma and Hodgkin's disease. A Phase II trial of the Southwest Oncology Group.
    Knight WA; Fabian C; Costanzi JJ; Jones SE; Coltman CA
    Invest New Drugs; 1983; 1(3):235-7. PubMed ID: 6678871
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of VP-16-213 in malignant lymphoma and melanoma.
    Cecil JW; Quagliana JM; Coltman CA; Al-Sarraf M; Thigpen T; Groppe CW
    Cancer Treat Rep; 1978 May; 62(5):801-3. PubMed ID: 657164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
    Ho AD; Del Valle F; Haas R; Engelhard M; Hiddemann W; Rückle H; Schlimok G; Thiel E; Andreesen R; Fiedler W
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
    Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stop-flow in mediastinum and thorax for resistant lymphoma.
    Guadagni S; Russo F; Abate G; Pozone T; Capannolo B; Marsili L; D'Alessandro V; Amicucci G; Aigner KR
    Hepatogastroenterology; 2000; 47(32):378-82. PubMed ID: 10791194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.